LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that the Company will make a presentation at the 28th Annual ROTH Conference to be held on March 13 - 16, 2016 at the Ritz Carlton Hotel, Dana Point, California.
The Company’s management will present on Tuesday, March 15, 2016 at 12:00 p.m. PT / 3:00 p.m. EST/ 9:00 p.m. CET.
The simultaneous live webcast, including a slide presentation, can be accessed by logging onto http://wsw.com/webcast/roth30/register.aspx?conf=roth30&page=poxel.pa&url=http://wsw.com/webcast/roth30/poxel.pa/index.aspx or on the Poxel website at www.poxel.com. A replay of the webcast will be available on Poxel’s website shortly after the conclusion of the call and will be archived there for 30 days following the call.
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has started Phase 2b development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)